J&J
Johnson
Johnson's
a
agrees
agreed
as
an
and
analysts
antitrust
aimed
at
also
are
artery
after
$25bn
$25.4bn
$76
Guidant
deal
defibrillators
defibrillators,
demand
detected,
drug
Pharmaceutical
giant
give
generic
&
has
heart
heartbeat
healthcare
to
technology
that
than
the
tubes
buy
business.
because
been
battling
by
medical
mergers
more
move
firm
firms
fierce
for
force
fragmented
from
facing
(Â£13bn).
is
implant
industries
increase,
irregular
it
key
keep
producer
products
products.
problems
pressure
price.
pacemakers.
patent
pay
pointed
of
offsetting
on
out
or
overlapping
operations.
open
equipment
expirations,
expected
electric
each
combats
company
competition
costs.
could
cut
closing
such
said
said.
say
slowing
small
shock
share,
shed
some
stent
A
Analysts
reliance
regulators
rhythm
The
They
likely
under
unblocked.
used
number
while
which
when
widely
will
Meanwhile,
6%
Wednesday's
US
Stents